AMSBIO has introduced a collection of mutated SARS-CoV-2 spike proteins and recombinant antigens for the new virus variants - B.1.1.7 and B.1.351. These reagents can be used by researchers to evaluate the efficacy of the antibodies and identify targets for development of improved therapeutic drugs and vaccines.
News
Business clusters in the Oxford-Cambridge Arc region have strongly welcomed the government’s announcement today that it will identify the needs to propel the Arc’s innovation-led economy.
CAMBRIDGE, MASS., and LONDON – February 16, 2021 – Centessa Pharmaceuticals (“Centessa”) launched today as a novel asset-centric pharmaceutical company designed and built to advance a portfolio of highly validated programs. Centessa’s asset-centric R&D model applied at scale has assembled best-in-class or first-in-class assets, each of which is led by specialized teams committed to accelerate development and reshape the traditional drug development process.
Cambridge, UK, 15 February 2021: Chesterford Research Park is delighted to welcome material research company Superdielectrics to the Park’s prestigious Science Village.
Cambridge, 15th February 2021: The Babraham Research Campus is delighted to welcome the charity Kidney Research UK as the latest organisation to pledge strategic and financial support to its Accelerate@Babraham initiative. The additional funding boosts the ability of the Campus to continue to support and sustain innovation in early science concepts and nurture new life science companies across the Cambridge cluster.
Fast growing food safety testing firm Curtis Analytics relocates to Discovery Park
Entrepreneurial scientist Dr Tanya Curtis plans further expansion & new business ideas
A technology-driven spin out that looks to transform cell production is the latest business to move into The Biosphere lab facility on Newcastle Helix.
Results from the first major business survey for 2021 by the Chambers of Commerce on Brexit found that half (49%) of exporters are facing difficulties in adapting to the changes in the trade of goods following the ratification of the UK-EU Trade and Cooperation Agreement (TCA) on 1 January 2021.
Cambridge, UK, and New York City, USA, 11 February 2021: Artios Pharma Limited (“Artios”), a leading DNA Damage Response (DDR) company developing a broad pipeline of precision medicines for the treatment of cancer, today announced the start of a clinical trial of its small-molecule ATR inhibitor, ART0380, in patients with advanced or metastatic solid tumors.
Quotient Sciences, the drug development and manufacturing accelerator, announced that it has acquired Arcinova, the U.K.-based multiservice contract development and manufacturing organization (CDMO). With over 40 years of experience and 160 employees, Arcinova provides drug substance, drug product and bioanalysis services to over 200 pharma and biotech customers worldwide.